top of page

Арис Ангуридис

Интернист

Доктор Арис Ангуридис - специалист в области внутренней медицины. В 2007 году он окончил Медицинскую школу Национального и Каподистрийского университета Афин, Греция. 

Прошел подготовку в качестве врача-интерниста в Университетской больнице Иоаннины, Греция (квалификация врача 2016 года). В 2017 году получил докторскую степень (PhD) в Медицинской школе Университета Янины, Греция. 

Также имеет степень аспиранта (MSc) по программе «Методология исследований в биомедицине, биостатистика и клиническая биоинформатика» в Фессалийском университете (2021). Специализировался на липидных нарушениях и профилактике сердечно-сосудистых заболеваний в Королевской свободной больнице, Лондон, Великобритания (2014-2015 гг.), получив стипендию от Греческого общества атеросклероза. Он опубликовал более 63 работ в рецензируемых журналах с более чем 1330 ссылками и имеет индекс H 22. 


В настоящее время является доцентом кафедры внутренней медицины/патофизиологии и нарушений метаболизма липидов в Европейском университете Кипра и консультантом Немецкого медицинского института, Лимассол, Кипр.

dct-VhrachimisAl.jpg

Образование / академический опыт

  • 2001 - 2007: Степень (ptychio) в области медицины, Национальный и Каподистрийский университет Афин, Греция. Оценка: «Очень хорошо».

  • 2008 - 2017: Доктор философии «Эффективность высоких доз розувастатина в сравнении с низкими дозами розувастатина плюс фенофибрат в сравнении с низкими дозами розувастатина плюс омега-3 жирные кислоты в лечении смешанной гиперлипидемии». Кафедра внутренней медицины, медицинская школа, Университет Иоаннины, 45110 Иоаннина, Греция. Амбулаторная липидная клиника университетской больницы Янины, Греция. Руководитель: МС Элисаф. Оценка: «Отличие».

  • Сентябрь 2020 - сентябрь 2021: Магистерская программа аспирантуры «Методология исследований в биомедицине, биостатистика и клиническая биоинформатика», Медицинская школа, Лариса, Фессалийский университет.

  • 24/09/2018 - 31/10/2021: Преподаватель внутренней медицины/патофизиологии и нарушений метаболизма липидов в Европейском университете Кипра, Никосия, Кипр

  • 01/11/2021 - по настоящее время доцент кафедры внутренней медицины/патофизиологии и нарушений метаболизма липидов в Европейском университете Кипра, Никосия, Кипр

Профессиональный опыт

  • 17/12/2007 – 18/01/2016: Research Fellow in the Outpatient Lipid Clinic of the University Hospital of Ioannina, Greece.

    Address: Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece.

  • 26/03/2010 – 25/06/2010: Rural General Practitioner in General Hospital of “G. Hatzikosta”, Ioannina, Greece.

  • 26/06/2010 – 27/03/2011: Rural General Practitioner in Health Centre of Pramanta and Health Unit of Kalarrytes, Ioannina, Greece.

  • 16/05/2011 – 31/12/2015: Specialty Training post in the 2nd Department of Internal Medicine at General University Hospital of Ioannina, Greece. Head of the Department: Prof MS Elisaf

  • 26/09/2014 – 15/03/2015: Honorary Clinical Research Fellow for a period of 6 months in the Department of Clinical Biochemistry, Royal Free Hospital, London, after receiving a scholarship from the Hellenic Atherosclerosis Society.

    Head of the Department: Prof DP Mikhailidis

  • 09/03/2016 – 09/12/2016: Mandatory Military Service of nine months regular duty in the Greek army

  • 14/03/2017 – 01/10/2018: Specialty Training post in the 2nd department of Intensive Care Unit at General Hospital of Attica, KAT.

  • 21/04/2020 – up to date Consultant in Internal Medicine, Department of Internal Medicine, German Medical Institute, Limassol, Cyprus Medical Director: Nikolaos Zamboglou

Сертификация и курсы

  • 03/11/2018: Received the ERC qualification Advanced Life Support (ALS) in Athens, Greece

  • 03/11/2023: Received the ERC qualification Advanced Life Support (ALS) in Ioannina, Greece

Публикации

  1. Agouridis AP, Filippatos TD, Kostara C, Tsimihodimos V, Kostapanos MS. The Effect of Low, Moderate, and High Doses of Rosuvastatin on Lipoprotein(a) Levels in Hyperlipidemic Patients with Impaired Fasting Glucose: A Post-Hoc Analysis. Turk Kardiyol Dern Ars. 2024 ;52(8) (ahead of print).

  2. Messaritakis I, Vougiouklakis G, Koulouridi A, Agouridis AP, Spernovasilis N. Hidden army within: Harnessing the microbiome to improve cancer treatment outcomes. World J Clin Cases. 2024 Oct 6;12(28):6159-6164.

  3. AlRawashdeh MM, Ishak A, Al-Bunnia A, Agouridis AP, Lytras T, Spernovasilis N, Tsioutis C. Patient Experiences and Perceptions with Infections Due to Multidrug-Resistant Organisms: A Systematic Review. Pathogens. 2024 Sep 22;13(9):817.

  4. Vougiouklakis G, Agouridis AP, Alexakis K, Mamilos A, Spernovasilis N. Herpes Simplex Virus Esophagitis in a Patient Receiving Long-Term Nasal Corticosteroids: A Rare Case. Cureus. 2024 Aug 11;16(8):e66631.

  5. Harikrishna A, Chatzidakis S, Ishak A, Faropoulos K, Fotakopoulos G, Georgakopoulou VE, Sklapani P, Trakas N, Yiallouris A, Iosif C, Agouridis AP, Hadjigeorgiou G. Awake craniotomy in patients with arteriovenous malformation: A systematic review and meta‑analysis. Med Int (Lond). 2024 Jun 6;4(4):42.

  6. Rizos EC, Tagkas CF, Asimakopoulos AI, Tsimihodimos V, Anastasiou G, Rizzo M, Agouridis AP, Ntzani EE. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials. J Diabetes Complications. 2024 Jul;38(7):108781.

  7. Agouridis AP, Mastori-Kourmpani C, Antoniou P, Konstantinou P, Rizos EC, Tsioutis C. Beau's Lines and COVID-19; A Systematic Review on Their Association. Pathogens. 2024 Mar 20;13(3):265.

  8. Agouridis AP, Filippatos TD, Kostapanos M, Kostara C, Tsimihodimos V. The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia. Arch Med Sci Atheroscler Dis. 2024 Feb 19;9:e26-e32.

  9. Pagkali A, Makris A, Brofidi K, Agouridis AP, Filippatos TD. Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease. Diabetes Metab Syndr Obes. 2024 Jan 22;17:283-294.

  10. Agouridis AP, Ntzani EE, Anastasiou G, Barkas F, Rizos EC. Unravelling Beau’s lines as a potential indicator of severe immune response in COVID-19 and reinfection. EJCRIM 2024;10.

  11. Kandarakis SA, Spernovasilis N, Georgalas I, Mendris M, Tsioutis C, Agouridis AP. Endophthalmitis caused by Enterococcus casseliflavus: a systematic review of literature. GERMS. 2023;13(4):343-351.

  12. Agouridis AP, Karageorgos SA, Tsioutis C. Role of gender in hesitancy toward the COVID-19 vaccine beyond medical students. GERMS. 2023;13(4):385-387.

  13. Lena P, Karageorgos S, Liatsou M, Agouridis AP, Spernovasilis N, Lamnisos D, Papageorgis P, Tsioutis C. In vitro study on the transmission of multidrug-resistant bacteria from textiles to pig skin. World J Exp Med. 2023 Dec 20;13(5):134-141.

  14. Makris A, Pagkali A, Nikolousis E, Filippatos TD, Agouridis AP. High-density lipoprotein cholesterol and multiple myeloma: A systematic review and meta-analysis. Atheroscler Plus. 2023 Sep 21;54:7-13.

  15. Agouridis AP, Palli N, Karagiorga VE, Konsoula A, Markaki L, Spernovasilis N, Tsioutis C. Statins in Children with Neurofibromatosis Type 1: A Systematic Review of Randomized Controlled Trials. Children (Basel). 2023 Sep 15;10(9):1556.

  16. Agouridis AP, Filippatos TD. Interleukin-6 Inhibition and Lipoprotein(a): An Association Requiring More Research. Curr Pharm Des. 2023;29(27):2113-2115.

  17. Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Filippatos TD, Ray KK, Agouridis AP. Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association? Atheroscler Plus. 2023 Sep 9;54:1-6.

  18. Symvoulidis P, Tsioutis C, Zamboglou C, Agouridis AP. The Effect of Statins on the Incidence and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis. Curr Oncol. 2023 Jul 12;30(7):6648-6665.

  19. Lymperopoulou C, Kandarakis SA, Tzanaki I, Mylona I, Xanthos T, Agouridis AP. The Effect of Statins on Ocular Disorders: A Systematic Review of Randomized Controlled Trials. Pharmaceuticals (Basel). 2023 May 7;16(5):711.

  20. Spernovasilis N, Agouridis AP, Tsioutis C. Appropriate antimicrobial use during the COVID-19 pandemic: not cause for complacency. Lancet Microbe. 2023 May;4(5):e293.

  21. Konsoula A, Agouridis AP, Markaki L, Tsioutis C, Spernovasilis N. Lomentospora prolificans Disseminated Infections: A Systematic Review of Reported Cases. Pathogens. 2022 Dec 31;12(1):67.

  22. Strouthou E, Karageorgos SA, Christaki E, Agouridis AP, Tsioutis C. Medical students' attitudes and perceptions of influenza and SARS-CoV-2 vaccination in Cyprus. Germs. 2022 Jun 30;12(2):180-194.

  23. Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Agouridis AP. The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2022 Nov 22;11(23):6894.

  24. Samouilidis A, Beltsios ET, Mavrovounis G, Adamou A, Belios I, Hadjivasilis A, Pantazopoulos I, Agouridis AP. The Use of Antenatal Dexamethasone in Late Preterm and Term Pregnancies to Improve Neonatal Morbidity and Mortality: A Systematic Review and Meta-Analysis. Cureus. 2022 Aug 10;14(8):e27865.

  25. Konsoula A, Tsioutis C, Markaki I, Papadakis M, Agouridis AP, Spernovasilis N. Lomentospora prolificans: An Emerging Opportunistic Fungal Pathogen. Microorganisms. 2022 Jun 29;10(7):1317.

  26. Germanou D, Spernovasilis N, Papadopoulos A, Christodoulou S, Agouridis AP. Infections Caused by Moellerella wisconsensis: A Case Report and a Systematic Review of the Literature. Microorganisms. 2022 Apr 24;10(5):892.

  27. Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol. 2022 Jan 27;14(1):119-139.

  28. Pagkali A, Mamais I, Michalinos A, Agouridis AP. Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis. Curr Oncol. 2022 Jan 12;29(1):321-336.

  29. Agouridis AP, Pagkali A, Zintzaras E, Rizos EC, Ntzani EE. High-density lipoprotein cholesterol: A marker of COVID-19 infection severity? Atheroscler Plus. 2021 Oct;44:1-9.

  30. Manolopoulos PP, Lavranos G, Mamais I, Angouridis A, Giannakou K, Johnson EO. Vitamin D and bone health status in beta thalassemia patients-systematic review. Osteoporos Int. 2021 Jun;32(6):1031-1040.

  31. Florentin M, Parthymos I, Agouridis AP, Liamis G. Hyperemesis Gravidarum: A Benign Condition of Pregnancy or a Challenging Metabolic Disorder? Eur J Case Rep Intern Med. 2020 Oct 16;7(12):001979.

  32. Hadjivasilis A, Tzanis A, Ioakim KJ, Poupoutsi I, Agouridis AP, Kouis P. The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):312-318.

  33. Michalinos A, Antoniou SA, Ntourakis D, Schizas D, Ekmektzoglou K, Angouridis A, Johnson EO. Gastric ischemic preconditioning may reduce the incidence and severity of anastomotic leakage after οesophagectomy: a systematic review and meta-analysis. Dis Esophagus. 2020 Oct 12;33(10):doaa010.

  34. Agouridis AP. Anterior Tragal Crease: A Marker of Coronary Artery Disease. Angiology. 2020 Oct;71(9):791-792.

  35. Sfairopoulos D, Tsiara S, Barkas F, Margariti PN, Agouridis AP, Tsioutis C, Ntzani EE, Rizos EC. Is brucellosis a great mimic of tuberculosis? A case report. Eur J Clin Microbiol Infect Dis. 2020 Sep;39(9):1711-1715.

  36. Kleinaki Z, Agouridis AP, Zafeiri M, Xanthos T, Tsioutis C. Epicardial adipose tissue deposition in patients with diabetes and renal impairment: Analysis of the literature. World J Diabetes. 2020 Feb 15;11(2):33-41.

  37. Hadjivasilis A, Tsioutis C, Michalinos A, Ntourakis D, Christodoulou DK, Agouridis AP, New Insights for Irritable bowel syndrome: From Pathophysiology to Treatment. Ann Gastroenterol. 2019 Nov-Dec;32(6):554-564

  38. Yialloyris A, Tcioutis C, Agapidaki E, Zafeiri M, Agouridis AP, Ntourakis D, Johnson EO, Adrenal Aging and Its Implications on Stress Responsiveness on Humans. Front Endocrinol 2019 Feb 7;10:54

  39. Chantzichristos VG, Agouridis AP, Moutzouri E, et al. Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. Atherosclerosis 2016;251:240-7.

  40. Chantzichristos VG, Agouridis AP, Moutzouri E, et al. Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study. Curr Vasc Pharmacol 2016;14:474-80.

  41. Agouridis AP, Elisaf MS, Nair DR, et al. Ear lobe crease: a marker of coronary artery disease? Arch Med Sci 2015;11:1145-55.

  42. Agouridis AP, Elisaf MS, Nair DR, et al. All for Statins and Statins for All; An Update. Curr Pharm Des 2015;22:18-27.

  43. Agouridis AP, Kostapanos MS, Elisaf MS. Statins and their increased risk of inducing diabetes. Expert Opin Drug Saf 2015;14:1835-44.

  44. Kostapanos MS, Agouridis AP, Elisaf MS. Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia. 2015 Aug;58(8):1960-1.

  45. Agouridis AP, Banach M, Mikhailidis DP. Dysfunctional HDL: not only quantity but first of all quality? Arch Med Sci. 2015 Mar 16;11(1):230-1.

  46. Agouridis AP, Filippatos TD, Katsiki N. Current lipid-modifying agents. Expert Opin Pharmacother. 2015 May;16(7):1117-8.

  47. Agouridis AP, Nair DR, Mikhailidis DP. Strategies to overcome statin intolerance. Expert Opin Drug Metab Toxicol 2015; Jun;11:851-5.

  48. Agouridis AP, Mikhailidis DP. Should we consider ezetimibe for reaching even lower LDL-C target? Curr Med Res Opin 2015;20:1-2.

  49. Agouridis AP, Rizos CV, Elisaf MS, Filippatos TD. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud. 2013 10(2-3):171-90.

  50. Filippatos TD, Rizos EC, Gazi IF, Lagos k, Agouridis A, Mikhailidis DP, Elisaf MS. Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. Arch Med Sci. 2013 9(5):788-95.

  51. Agouridis AP, Liberopoulos EN, Kostapanos MS, Elisaf MS. New-onset extremely low levels of high-density lipoprotein cholesterol. J Clin Lipidol. 2012 6:593-5.

  52. Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract. 2012. 66(9):843-53.

  53. Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther. 2012 Dec;17(4):382-6.

  54. Rizos EC, Agouridis AP, Elisaf MS. Aliskiren in patients with diabetes: a systematic review. Curr Vasc Pharmacol. 2012 Mar 1;10(2):140-6.

  55. Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis CC, Elisaf MS, Mikhailidis DP, Tselepis AD. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother. 2011 Dec;12(17):2605-11.

  56. Agouridis AP, Filippatos TD, Tsimihodimos V, Elisaf MS. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther. 2011 Mar;9(3):355-66.

  57. Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS, “High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia”. Lipids. 2011 Jun;46(6):521-8.

  58. Agouridis, AP, Elisaf MS, Milionis HJ, “An overview of lipid abnormalities in patients with inflammatory bowel disease” Ann Gastroenterol, 2011. 24(3):181-187.

  59. Agouridis AP, Filippatos TD, Derdemezis CS, Mikhailidis DP, Elisaf MS. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des. 2010 Oct;16(30):3401-16.

  60. Liberopoulos EN, Florentin M, Kei A, Mountzouri E, Agouridis A, Elisaf MS. Comparison of hemoglobin A1c and fasting glucose criteria to diagnose diabetes among people with metabolic syndrome and fasting glucose above 100 mg/dL (5.5 mmol/L). J Clin Hypertens (Greenwich). 2010 Jul 1;12(7):543-8.

  61. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010 Sep;8(5):638-44.

  62. Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids. 2010 May;45(5):445-50.

  63. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract. 2009 Sep;63(9):1308-13.

Профессиональные членства

  • 12/09/2007: Licence to Practice Medicine, Ref. No: 8500. Hellenic Republic, Prefectural Authority of Athens – Piraeus, Prefecture of Athens, Division of Eastern Athens, Greece.

  • 18/01/2016: Licence to practise the qualification of Medical Specialty: “Internal Medicine”. Registration Number: 117786/4195/2015. Hellenic Republic, Region of Epirus, General Directorate of Public Health and Social welfare, Directorate of Public Health, Greece.

  • 26/06/2014 – 03/01/2017: Fully registered as a medical practitioner with Full License to Practice with the General Medical Council (UK), GMC number: 7479508.

  • 03/01/2017 – up to date Registered as a medical practitioner with the General Medical Council (UK), GMC number: 7479508.

  • 28/05/2019 – up to date Registered as a medical practitioner with the Cyprus Medical Council, Registration number: 6613

  • 2022 – up to date: Board Member of the Cyprus Atherosclerosis Society (CAS)

  • 2007 – up to date: Member of the Hellenic Atherosclerosis Society (HAS)

    2020 – up to date: Member of the European Atherosclerosis Society (EAS)


bottom of page